Alexandre Savio

Alexandre Savio

Auto-generated profile, based on publicly available information

Alexandre Savio

Universidad del País Vasco (UPV/EHU)

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Neural Networks
Verified
Journal Article
Closed access
DCDarya Chyzhyk
Darya Chyzhyk
ASAlexandre Savio
Alexandre Savio
MGManuel Graña
Manuel Graña

2 March 2017 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
ASAlexandre Savio
Alexandre Savio
SFSarah Fünger
Sarah Fünger
MTMasoud Research Tahmasian
Masoud Research Tahmasian
SRSrinivas Rachakonda
Srinivas Rachakonda
AMAndrei Manoliu
Andrei Manoliu
IYIgor Yakushev
Igor Yakushev
Functional MRI (fMRI) studies reported disruption of resting-state networks (RSNs) in several neuropsychiatric disorders. PET with 18F-FDG captures neuronal activity that is in steady state at a longer time span and is less dependent on neurovascular coupling. Methods: In the present study, we aimed to identify RSNs in 18F-FDG PET data and compare their spatial pattern with those obtained from simultaneously acquired resting-state fMRI data in 22 middle-aged healthy subjects. Results: Thirteen and 17 meaningful RSNs could be identified in PET and fMRI data, respectively. Spatial overlap was fair to moderate for the default mode, left central executive, primary and secondary visual, sensorimotor, cerebellar, and auditory networks. Despite recording different aspects of neural activity, similar RSNs were detected by both imaging modalities. Conclusion: The results argue for the common neural substrate of RSNs and encourage testing of the clinical utility of resting-state connectivity in PET data.

1 February 2015 in Neurocomputing
Verified
Journal Article
Closed access
GPG.A. Papakostas
G.A. Papakostas
ASA. Savio
A. Savio
MGM. Graña
M. Graña
Vassilis KaburlasosVassilis Kaburlasos
Vassilis Kaburlasos

14 December 2015 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
ABAriadna Besga
Ariadna Besga
IGItxaso Gonzalez
Itxaso Gonzalez
EEEnrique Echeburúa
Enrique Echeburúa
ASAlexandre Savio
Alexandre Savio
BABorja Ayerdi
Borja Ayerdi
AGAna Maria Gonzalez-Pinto
Ana Maria Gonzalez-Pinto
Textbf{Background} Late Onset Bipolar Disorder (LOBD) is often difficult to distinguish from degenerative dementias, such as Alzheimer Disease (AD), due to comorbidities and common cognitive symptoms. Moreover, LOBD prevalence in the elder population is not negligible and it is increasing. Both pathologies share pathophysiological features related to neuroinflammation. Improved means to differentiate between LOBD and AD in elder subjects will help to select the best personalized treatment. \textbf{Objective} The aim of this study \textcolor{red}{was} to assess the relative significance of clinical observations, neuropsychological tests, and \textcolor{red}{specific} \textcolor{red}{blood plasma }biomarkers (inflammatory and neurotrophic), separately and combined, in the \textcolor{red}{differential diagnosis} of LOBD versus AD. The \textcolor{red}{significance} assessment \textcolor{red}{was} carried out evaluating the accuracy achieved by classification based computer aided diagnosis (CAD) systems based on these variables. \textbf{Materials} A sample of healthy controls (HC) (n=26), AD patients (n=37), and LOBD patients (n=32) \textcolor{red}{was} recruited at the Alava University Hospital. Clinical observations, neuropsychological tests, and plasma biomarkers \textcolor{red}{were} obtained at recruitment time. \textbf{Methods} We appl\textcolor{red}{ied} multivariate machine learning classification methods to discriminate subjects from HC, AD and LOBD populations in the study. We analyze\textcolor{red}{d} of feature sets \textcolor{red}{combining} clinical observations, neuropshycological measures, and biological markers, including inflammation biomarkers. \textcolor{red}{A feature set containing variables showing significative differences for each classification contrast was tested also.} Furthermore, a battery of classifier approaches \textcolor{red}{were} applied, encompassing linear and non-linear Support Vector Machines (SVM), Random Forests (RF), Classification and regression trees (CART), and their performance \textcolor{red}{was} evaluated in a leave-one-out \textcolor{red}{(LOO)} cross-validation scheme. Post-hoc analysis of Gini index in CART classifiers provided a measure of each variable importance. \textbf{Results} Welch's t-test found one biomarker (Malondialdehyde) with significative differences (p<0.001) in LOBD vs. AD contrast. Classification results with the best features are as follows: Discrimination of HC vs. AD patients reaches accuracy 97.21\%, AUC 98.17\%. Discrimination of LOBD vs. AD patients reaches accuracy 90.26\%, AUC 89.57\%. Discrimination of HC vs LOBD patients achieves accuracy 95.76\%, AUC 88.46\%.} \textbf{Conclusions} It is feasible to build CAD systems for discrimination among LOBD and AD \textcolor{red}{on the basis of a reduced set of clinical variables} to assist the clinician in this difficult differential

1 April 2013 in Expert Systems with Applications
Verified
Journal Article
Closed access
ASAlexandre Savio
Alexandre Savio
MGManuel Graña
Manuel Graña

1 September 2015 in Neurocomputing
Verified
Journal Article
Closed access
ASAlexandre Savio
Alexandre Savio
MGManuel Graña
Manuel Graña